



Defining Patient Populations for Clinical Studies in Multiple Myeloma

An FDA/IMS Joint Workshop



Oncology Center of Excellence



Meeting Roster

WORKSHOP CHAIRS

Nicole Gormley

Division Director of Hematologic Malignancies 2
U.S. Food and Drug Administration

Bindu Kanapuru

Associate Director of Therapeutic Review,
Division of Hematologic Malignancies II
U.S. Food and Drug Administration

Nikhil C. Munshi

Kraft Family Chair, Director of Basic and Correlative
Science, Professor of Medicine
Dana-Farber Cancer Institute, Harvard Medical School

SPEAKERS & MODERATORS

Kenneth C. Anderson

Dana-Farber Cancer Institute

Andrea Baines

U.S. Food and Drug Administration

Shaji Kumar

Mayo Clinic

Philippe Moreau

University Hospital of Nantes, France

Noopur Raje

Massachusetts General Hospital

S. Vincent Rajkumar

Mayo Clinic

Deepti Telaraja

U.S. Food and Drug Administration

PANELISTS

Jesus Berdeja

Sarah Cannon Research Institute

Yelak Biru

International Myeloma Foundation

Orlando Bueno

Abbvie

Natalie Callander

University of Wisconsin

Ajai Chari

University of California San Francisco

Faith Davies

Perlmutter Cancer Center, NYU Langone Health

Pierre Demolis

European Medicines Agency

Rachel Ershler

U.S. Food and Drug Administration

Rod Humerickhouse

Bristol Myers Squibb

Sundar Jagannath

Mount Sinai Medical Center

Zandra Klippel

Sanofi

Edward Laane

European Medicines Agency

Suzanne Lentzsch

Columbia University

PANELISTS, CONT.

Sagar Lonial

Emory University School of Medicine

Sham Mailankody

Memorial Sloan Kettering Cancer Center

María-Victoria Mateos

University Hospital of Salamanca

David Mitchell

Patients for Affordable Drugs

Odoardo Olimpieri

European Medicines Agency

Krina Patel

MD Anderson Cancer Center, University of Texas

Jesus San Miguel

University of Navarra

Jordan Schecter

Janssen

Alex Schwarsin

U.S. Food and Drug Administration

Saad Z. Usmani

Memorial Sloan Kettering Cancer Center

Michal Zwiewka

European Medicines Agency